Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

The antitumour action of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is mediated through tumour-selective antivascular effects and cytokine induction. This clinical phase I trial was conducted to examine its toxicity, maximum tolerated dose, pharmacokinetics (PK) and pharmacodynamics (PD). A second...

Descripción completa

Detalles Bibliográficos
Autores principales: Jameson, M B, Thompson, P I, Baguley, B C, Evans, B D, Harvey, V J, Porter, D J, McCrystal, M R, Small, M, Bellenger, K, Gumbrell, L, Halbert, G W, Kestell, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741109/
https://www.ncbi.nlm.nih.gov/pubmed/12799625
http://dx.doi.org/10.1038/sj.bjc.6600992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741109/
https://www.ncbi.nlm.nih.gov/pubmed/12799625
http://dx.doi.org/10.1038/sj.bjc.6600992

Ejemplares similares